# This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

> **NCT01676935** · PHASE2 · TERMINATED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 349 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ABT-126

## Key facts

- **NCT ID:** NCT01676935
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 349 (ACTUAL)
- **Why stopped:** Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676935, "This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01676935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*